Cell and Gene Therapy
News
70% increase in Phase I advanced therapy clinical trials in the UK in 2024
The number of ongoing advanced therapy clinical trials in the UK reached 187 in 2024, an increase of 7% compared from the previous year. This includes a significant approximate increase of 70% in the number of Phase I trials, which grew from 24 to 41. The data is presented in the Cell and Gene Therapy Catapult’s UK 2024 Advanced Therapy Medicinal Product (ATMP) Clinical Trials Database.
Offshore Renewable Energy
News
Offshore Renewable Energy Catapult signs MOU on floating offshore wind with Japan’s FLOWRA
The Offshore Renewable Energy Catapult and the Japanese Floating Wind Technology Research Association (FLOWRA) have signed a Memorandum of Understanding (MOU) to work together to reduce development risks and costs of floating offshore wind.
The MOU, signed in Tokyo on Friday 7th March, is the culmination of a nine month period of collaboration and will include personnel exchange, work on standardisation of component technologies and a test and demonstration alliance to facilitate large-scale technology development.
Offshore Renewable Energy
News
17 innovative UK companies selected for offshore wind readiness programme
The latest cohort of ambitious UK businesses targeting success in the burgeoning UK offshore wind sector has been announced as they join the national Fit 4 Offshore Renewables (F4OR) programme, delivered by the Offshore Renewable Energy Catapult and sponsored by the Offshore Wind Growth Partnership (OWGP). This is the second nationally based cohort chosen to receive tailored business support, focused on improving tender readiness and winning offshore wind contracts.
Cell and Gene Therapy
News
Network established to identify opportunities for regulation to support innovation within advanced therapies
A new network will foster collaboration among regulators, industry, and researchers to ensure there is a world-leading regulatory environment in the UK for advanced therapies that supports companies in the development, trial, and launch of these innovative treatments. Cell and Gene Therapy Catapult, an independent innovation and technology organisation specialising in the advancement of the cell and gene therapy industry, and the Birmingham Health Partners Centre for Regulatory Science and Innovation (CRSI) established the network with funding from Innovate UK and support from the MHRA.
Page 1 of 1